abstract |
The present invention addresses the issue of providing a malignant mesothelioma therapeutic agent and a method for selecting malignant mesothelioma patients. The issue can be solved by a malignant mesothelioma therapeutic agent that includes, as an effective component thereof, a compound that targets the oxytocin receptor. |